Melanoma Clinical Trial

A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors

Summary

The objective of this study is to assess safety and efficacy of BA3071 in solid tumors

View Full Description

Full Description

This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3071 in combination with a PD-1 blocking antibody, nivolumab, in patients with advanced solid tumors.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients must have measurable disease.
Age ≥ 18 years
CLTA-4 blocking-antibody naïve.
Adequate renal function
Adequate liver function
Adequate hematological function
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

Patients must not have clinically significant cardiac disease.
Patients must not have known non-controlled CNS metastasis.
Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.
Patients must not have had major surgery within 4 weeks before first BA3071 administration.
Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
Patients must not be women who are pregnant or breast feeding.

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

320

Study ID:

NCT05180799

Recruitment Status:

Recruiting

Sponsor:

BioAtla, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

The Angeles Clinic and Research Institute
Los Angeles California, 90025, United States More Info
Misty Guillen
Contact
310-231-2183
[email protected]
Roland Menendez
Contact
(310)231-2184
[email protected]
Inderjit Mehmi, MD
Principal Investigator
USC Norris Comprehensive Cancer Center
Los Angeles California, 90033, United States More Info
Diane Chun
Contact
[email protected]
Jacob Thomas, MD
Principal Investigator
Piedmont West
Atlanta Georgia, 30318, United States More Info
Dionne Jean
Contact
404-425-7927
[email protected]
Sharon Joseph
Contact
404-425-7937
[email protected]
Eyal Meiri, MD
Principal Investigator
Horizon Oncology Research, LLC
Lafayette Indiana, 47905, United States More Info
Lynley Bell
Contact
765-446-5111
[email protected]
Costantine Albany, MD
Principal Investigator
University Hospitals Cleveland Medical Center
Cleveland Ohio, 44106, United States More Info
Kimberly Thomas
Contact
[email protected]
Jennifer Selfridge, MD
Principal Investigator
Providence Cancer Institute
Portland Oregon, 97213, United States More Info
Annie Stadum
Contact
503-215-3577
[email protected]
Kim Sutcliffe
Contact
503-215-5763
[email protected]
Matthew Taylor, MD
Principal Investigator
University of Utah Huntsman Cancer Institute
Salt Lake City Utah, 84112, United States More Info
Susan Sharry
Contact
801-585-3453
[email protected]
Siwen Hu-Lieskovan, MD, PhD
Principal Investigator
Cancer Care Foundation
Miranda New South Wales, 2228, Australia More Info
Amy Erskine
Contact
8556 9303
[email protected]
Paul DeSousa, MD
Principal Investigator
Cancer Research South Australia
Adelaide South Australia, 5000, Australia More Info
Daniel Clark
Contact
83592565
[email protected]
Vineet Kwatra, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

320

Study ID:

NCT05180799

Recruitment Status:

Recruiting

Sponsor:


BioAtla, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.